论文部分内容阅读
目的:探讨肝动脉化疗栓塞(TACE)联合经皮肝穿刺门静脉置管持续灌注华蟾素注射液治疗原发性肝癌的价值。方法:对16例确诊为原发性肝癌患者先在数字减彩血管造影(DSA)下行超选择性肝动脉化疗栓塞,术后予护肝等治疗,1周内在超声引导下行经皮肝穿刺门静脉置管持续灌注化疗,灌注药物为华蟾素注射液。间隔4-6周重复上述治疗,每例治疗2-3周期。结果:全组病例均获得随访,无手术死亡及严重并发症。3个月后随访表明近期疗效确切。经治疗后肿瘤完全坏死者6例(37.5%),明显缩小者5例(31.25%),稳定者2例(12.5%),无效3例(18.75%)。所有病例仍在跟踪随访中。结论:TACE联合门静脉置管持续灌注华蟾素注射液治疗能有效灭活和抑制肿瘤,在原发性肝癌的治疗中具有重要的临床价值。
Objective: To investigate the value of transcatheter hepatic arterial chemoembolization (TACE) combined with percutaneous transhepatic portal vein catheterization continuous perfusion of cinobufacini injection in the treatment of primary liver cancer. Methods: Twenty-six patients diagnosed as primary hepatocellular carcinoma underwent digitalis angiography (DSA) undergoing transcatheter hepatic arterial chemoembolization and treated with liver protection after operation. One week after transcatheter percutaneous transhepatic portal vein Catheter continuous infusion chemotherapy, perfusion drug cinobufacini injection. The above treatment is repeated 4-6 weeks apart, 2-3 cycles per treatment. Results: All the patients were followed up without surgery and serious complications. Follow-up after 3 months shows that the recent curative effect is correct. After treatment, there were 6 cases (37.5%) with complete necrosis of the tumor, 5 cases (31.25%) with obvious reduction, 2 cases (12.5%) stable and 3 cases (18.75%) ineffective. All cases are still under follow-up. Conclusion: TACE combined with portal vein catheterization continuous infusion of cinobufacini injection can effectively inactivate and inhibit the tumor, in the treatment of primary liver cancer has important clinical value.